PCSK9 Inhibitors Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)
PCSK9 Inhibitors Market is segmented By Drug Type (Monoclonal antibodies, Small interfering mRNA), By Application (Cardiovascular Disease Treatment, Familial Hypercholesterolemia), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD billion) for the above-mentioned segments.
PCSK9 Inhibitors Market Size
Market Size in USD
CAGR16.2%
| Study Period | 2024 - 2031 |
| Base Year of Estimation | 2023 |
| CAGR | 16.2% |
| Market Concentration | High |
| Major Players | Amgen (REPATHA), Sanofi/Regeneron (PRALUENT), Merck (MK-0616), LIB Therapeutics (LIB003), AstraZeneca |
*Disclaimer: Major players are listed in no particular order.
*Source: Coherent Market Insights
Want to purchase customized report?
please let us know !
please let us know !
PCSK9 Inhibitors Market Analysis
The PCSK9 inhibitors market is estimated to be valued at USD 2.44 Bn in 2024 and is expected to reach USD 6 Bn by 2031, growing at a compound annual growth rate (CAGR) of 16.2% from 2024 to 2031. The major factors driving the growth of this market are the increasing cases of hypercholesterolemia and cardiovascular diseases among the growing geriatric population.